NeuroMetrix Announces Peer-Reviewed Publication Of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy
Portfolio Pulse from Benzinga Newsdesk
NeuroMetrix has announced that its Phase 2 clinical trial results, which show that Quell, its wearable pain relief device, improves symptoms of chemotherapy-induced peripheral neuropathy (CIPN), have been published in a peer-reviewed journal. This publication could potentially boost the credibility of Quell and NeuroMetrix's standing in the medical community.
December 05, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The peer-reviewed publication of NeuroMetrix's Phase 2 clinical trial results for Quell is a positive development, potentially increasing investor confidence in the company's product pipeline and its ability to address CIPN.
The publication of positive clinical trial results in a peer-reviewed journal is a significant milestone for medical products. It enhances the product's scientific credibility and can lead to increased interest from the medical community, potentially boosting sales. For investors, this news could signal future revenue growth and partnerships, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100